News / Publication

By developing a support program for evaluating neoadjuvant therapy effectiveness, Chugai and Biomy aim to improve pathology diagnosis throughput and standardize pathologic response assessment, contributing to optimal treatment selection for patients  By developing a program that detects features related to prognosis and drug efficacy from the tumor microenvironment, the two companies aim to realize personalized healthcare and maximize the value of pharmaceuticals    TOKYO, No

Biomy announced the presentation of abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago,...

Tokyo, Japan, January 10, 2025  – NEC Corporation (NEC; TSE: 6701) and Biomy, Inc. (Biomy) have signed a Memorandum of Understanding...

Biomy, Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Teppei Konishi; hereinafter referred to as "our company"), which boasts advanced...

Biomy has been selected by the Ministry of Economy, Trade and Industry (METI) for a grant project worth approximately 100 million yen....

Tokyo, Japan, – Biomy Inc. announced today that, effective 1st April, 2024, it has become a member of Johnson & Johnson Innovation –...

Biomy announced the presentation of abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago,...

We are excited to announce that Biomy will present research at NVIDIA GTC 2024! NVIDIA GTC 2024 Thursday, Mar 21 11:00 PM - 11:25 PM PDT...

We have been officially approved by the Tokyo Metropolitan Government as "Medical Devices Marketing license（第二種医療機器製造販売業許可 許可番号...

We will introduce our service for analyzing tumor microenvironments at this event. https://www.healthtechsum.jp/program_day1.html

We will introduce our project in the event. https://chugai-digital-innovation-lab-2023.peatix.com/ 日時 ：2023年11月1日（水）12:30～14:30...

Biomy announced the presentation of 2 abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in...

We will be speaking at the MEDISO-sponsored seminar on 2022.11.25. Event details (Jump to LINK-J website) MEDISO will be holding regular...

biomy Inc. has been selected by MEDISO to receive support for its human resource exchange program commissioned by the Ministry of Health,...

Biomy, Inc(Head office: Shibuya-ku, Tokyo; President: Teppei Konishi; hereinafter "biomy"), has raised funds from Shinnihon Scientific...

Microsoft Japan, Inc. and we will hold a luncheon seminar at the 4th Annual Meeting of the Japanese Society for Medical AI We will hold a...

biomy, Inc. has been selected for NVIDIA INCEPTION, a startup program offered by NVIDIA Corporation. NVIDIA Inception is a free program...

Update: March 27, 2022 biony (Headquarters: Shibuya-ku, Tokyo, Japan) has been selected by Microsoft Corporation (Headquarters:...

biony (Head office: Shibuya-ku, Tokyo; CEO: Teppei Konishi) has been selected for the X-HUB OUTBOUND PROGRAM 2021 NY Course, sponsored by...

Update: January 27, 2022 November 16, 2021 Our efforts were introduced to UK biotech companies/investors at the JHVS2021 Global Pitch. We...